Core Viewpoint - Investors in Theravance Biopharma, Inc. (TBPH) should closely monitor the stock due to significant movements in the options market, particularly the March 20, 2026 $10 Put option which has high implied volatility [1] Group 1: Implied Volatility - Implied volatility indicates the market's expectation of future stock movement, with high levels suggesting anticipation of a significant price change or an upcoming event that could trigger a rally or sell-off [2] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of the option's value if the stock does not move as expected [4] Group 2: Analyst Sentiment - Theravance Biopharma currently holds a Zacks Rank 3 (Hold) within the Medical – Drugs industry, which is in the top 39% of the Zacks Industry Rank [3] - Over the past 60 days, no analysts have increased earnings estimates for the current quarter, while one has decreased them, resulting in a drop in the Zacks Consensus Estimate from 46 cents per share to 44 cents [3]

Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and knowledge [1] - The Zacks Style Scores are complementary indicators that help investors select stocks likely to outperform the market in the short term [3] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each assessing different investment characteristics [4][5][6][7] - Value Score focuses on identifying undervalued stocks using financial ratios [4] - Growth Score evaluates stocks based on their future earnings and financial health [5] - Momentum Score identifies trends in stock prices and earnings outlooks to guide investment timing [6] - VGM Score combines all three Style Scores to highlight stocks with the best overall potential [7] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify stock selection [8] - Stocks rated 1 (Strong Buy) have historically outperformed the S&P 500, with an average annual return of +23.9% since 1988 [9] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [11] Company Spotlight: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, formed from a split in 2014 [12] - TBPH currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of A [12] - The company has a Momentum Style Score of B, with shares increasing by 10.7% over the past four weeks [13] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising by $0.01 to $0.24 per share [13] - TBPH has an average earnings surprise of +55.4%, making it a notable candidate for investors [13]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]

Core Viewpoint - Theravance Biopharma (TBPH) shares have increased by 1.7% over the past four weeks, closing at $18.79, with a mean price target of $26.71 indicating a potential upside of 42.2% according to Wall Street analysts [1] Price Targets - The average price target consists of seven estimates ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1, indicating variability among analysts [2] - The lowest estimate suggests a decline of 30.8% from the current price, while the highest estimate indicates a potential upside of 123.5% [2] Analyst Sentiment - Analysts are optimistic about TBPH's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TBPH's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Viewpoint - Theravance Biopharma is focusing on ampreloxetine, an orphan drug aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy, with pivotal Phase III study data expected in Q1 2026 [2][3]. Group 1: Product Overview - Ampreloxetine is designed to address a significant unmet need in symptomatic neurogenic orthostatic hypotension (nOH) [3]. - The drug is positioned as a once-daily oral medication that offers a durable treatment effect, potentially transforming the treatment landscape for affected patients [3]. Group 2: Clinical Development - The pivotal Phase III study, named CYPRESS, is nearing completion, with results anticipated in the first quarter of 2026 [2].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Theravance Biopharma (TBPH) - Theravance Biopharma currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [4] Performance Metrics - TBPH shares have increased by 9.85% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 4.47% during the same period [6] - Over the past month, TBPH's price change is 25.76%, significantly higher than the industry's 0.88% [6] - In the last quarter, TBPH shares rose by 29.72%, and over the past year, they have gained 87.75%, while the S&P 500 increased by only 6.25% and 14.29%, respectively [7] Trading Volume - TBPH's average 20-day trading volume is 594,234 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, 2 earnings estimates for TBPH have been revised upwards, while only 1 estimate was revised downwards, leading to an increase in the consensus estimate from -$0.06 to $0.24 [10] - For the next fiscal year, 3 estimates have moved upwards with no downward revisions, indicating positive sentiment regarding future earnings [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, TBPH is positioned as a promising investment opportunity with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Theravance Biopharma Conference Call Summary Company Overview - **Company**: Theravance Biopharma - **Focus**: Development of Ampraloxetine for treating neurogenic orthostatic hypotension (NOH) in patients with multiple system atrophy (MSA) [2][4][5] Industry Context - **Target Disease**: Neurogenic orthostatic hypotension (NOH) associated with multiple system atrophy (MSA) - **Patient Population**: Approximately 40,000 MSA patients in the U.S. with NOH [6][44] - **Current Treatment Landscape**: Existing therapies (midodrine, droxidopa) provide only transient relief and are not effective for MSA [46][47] Key Points and Arguments Ampraloxetine Development - **Phase 3 Study**: The pivotal CYPRESS study is nearing completion, with data expected in Q1 2026 [2][5] - **Mechanism of Action**: Ampraloxetine is a selective norepinephrine transporter (NET) inhibitor designed to enhance norepinephrine levels, thereby improving blood pressure and symptoms in NOH patients [31][19] - **Clinical Evidence**: Previous studies indicated that 70% of MSA patients remain symptomatic despite current treatments, highlighting the unmet need [18][46] Financial Position - **Cash Reserves**: Theravance ended the last quarter with $333 million in cash and no debt, achieving cash flow break-even [5] - **Milestones**: Expected near-term milestones of $175 million from existing products (Trelegy and Yupelri) [5] Clinical Trial Insights - **CYPRESS Study Design**: The study incorporates lessons from the previous REDWOOD study, focusing on a randomized withdrawal design to assess treatment effects [32][34] - **Primary Endpoint**: The Orthostatic Hypotension Symptom Assessment (OHSA) composite score is selected as the primary endpoint, reflecting the full spectrum of NOH symptoms [34][38] Market Opportunity - **Commercial Strategy**: Targeting a concentrated patient population with a lean commercial infrastructure, focusing on centers of excellence [44][51] - **Physician Sentiment**: High interest from physicians, with 90% of neurologists likely to prescribe Ampraloxetine if approved [48] - **Pricing Expectations**: Anticipated pricing aligns with other rare disease therapies, potentially around $300,000 annually per patient [57] Regulatory Engagement - **FDA Interactions**: Positive feedback from the FDA regarding the study design and primary endpoint, indicating alignment for a potential NDA submission [38][42] Additional Important Insights - **Safety Profile**: Ampraloxetine has shown an acceptable safety profile with low side effects and no worsening of supine hypertension [40] - **Global Market Potential**: Opportunities exist beyond the U.S. in Europe and Asia, with established relationships in key opinion leader networks [58] Conclusion - **Future Outlook**: If CYPRESS data is positive, Ampraloxetine could become the first tailored treatment for NOH in MSA, addressing a significant unmet medical need and establishing a new standard of care [60]

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

Core Viewpoint - Theravance Biopharma (TBPH) has seen a 25.8% increase in share price over the past four weeks, closing at $18.7, with a mean price target of $24.43 indicating a potential upside of 30.6% [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $8.85, where the lowest estimate is $13.00 (indicating a 30.5% decline) and the highest is $40.00 (indicating a 113.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising TBPH's earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 69.6%, with two estimates moving higher and one lower [12] Zacks Rank and Investment Potential - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of potential gains, but the implied direction of price movement appears to be a useful guide [14]